APA

Yu M., Hung C., Huang Y., Peng C., Lin C., Cheng P., Chien R., Hsu S., Liu C., Huang C., Su C., Huang J., Liu C., Kao J., Chuang W., Chen P. & Chen D. (20190501). Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. : Journal of the Formosan Medical Association = Taiwan yi zhi.

Chicago

Yu Ming-Lung, Hung Chao-Hung, Huang Yi-Hsiang, Peng Cheng-Yuan, Lin Chun-Yen, Cheng Pin-Nan, Chien Rong-Nan, Hsu Shih-Jer, Liu Chen-Hua, Huang Chung-Feng, Su Chien-Wei, Huang Jee-Fu, Liu Chun-Jen, Kao Jia-Horng, Chuang Wan-Long, Chen Pei-Jer and Chen Ding-Shinn. 20190501. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. : Journal of the Formosan Medical Association = Taiwan yi zhi.

Harvard

Yu M., Hung C., Huang Y., Peng C., Lin C., Cheng P., Chien R., Hsu S., Liu C., Huang C., Su C., Huang J., Liu C., Kao J., Chuang W., Chen P. and Chen D. (20190501). Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. : Journal of the Formosan Medical Association = Taiwan yi zhi.

MLA

Yu Ming-Lung, Hung Chao-Hung, Huang Yi-Hsiang, Peng Cheng-Yuan, Lin Chun-Yen, Cheng Pin-Nan, Chien Rong-Nan, Hsu Shih-Jer, Liu Chen-Hua, Huang Chung-Feng, Su Chien-Wei, Huang Jee-Fu, Liu Chun-Jen, Kao Jia-Horng, Chuang Wan-Long, Chen Pei-Jer and Chen Ding-Shinn. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. : Journal of the Formosan Medical Association = Taiwan yi zhi. 20190501.